期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

一种高纯度奥司他韦磷酸盐中间体的制备方法

One Kind of Preparation Method for High-purity Intermediate of Oseltamivir Phosphate
下载PDF
导出
摘要 目的 制备高纯度奥司他韦重要中间体5-(戊烷-3-基氧基)-7-氧代-双环[4.1.0]庚-3-烯-3-羧酸乙酯。方法 以莽[艹旱]酸为起始原料,通过5步合成制备奥司他韦重要中间体,在制备过程中通过结晶方法去除杂质。结果与结论 此工艺操作简单,环境友好,适合于工业化生产。 OBJECTIVE To prepare of important high purity Oseltamivir intermediate 5-(pentane-3-yl)-7-oxy-dicyclic[4.1.0]hept-3-ene-3-carboxylic acid ethyl ester.METHODS Starting from shikimic acid, the title compound is synthesized in five chemical steps and high-purity compound was prepared through crystallization.RESULTS and CONCLUSION This process is easy to operate, environmentally friendly and suitable for industrial production.
作者 蔡福武 CAI Fu-wu(Fujian Province FUKANG Pharmaceutical Ltd.,Fuzhou 350309,China)
机构地区 福建省福抗药业股份有限公司
出处 《海峡药学》 2022年第11期82-84,共3页 Strait Pharmaceutical Journal
关键词 奥司他韦磷酸盐 莽[艹旱]酸 合成 结晶 Oseltamivir phosphate Shikimic acid Synthesize Crystallization
分类号 R917 [医药卫生—药物分析学]
  • 相关文献

参考文献3

二级参考文献14

  • 1Kim CU, Lew W, Williams MA, et al. Influenza neuraminidasc inhibitors possessing a novel hydrophobic interaction in the enzyme active site. J Am Chem Soc, 1997,119:681-690.
  • 2Hayden FG, Treanor J J, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza:randomized eontrolled trials for prevention and treatment. JAMA,1999,282 : 1240 -1246.
  • 3Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med, 1999,341 : 1336-1343.
  • 4Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA, 2000, 283:1016-1024.
  • 5Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficicy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet, 2000,355:1845-1850.
  • 6Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis, 1999,180:254-261.
  • 7Massarella JW, He GZ, Dorr A, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers[J]. Clin Pharmacol,2000.40:836.
  • 8Treanor J J, Hayden FG, Vrooman PS, et al. Efficacy and safety of oral neuraminidase inhibitor oseltamivir in treating acute influenza [J]. JAMA, 2000,283(8):1061.
  • 9Wiltshire H, Wiltshire B, Citron A, et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of RO 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine[J]. J Chromatography B, 2000,745: 373.
  • 10He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802 [J]. Clin Pharmacokinet, 1999,37(6) :471.

共引文献72

海峡药学
2022年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部